Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy SELLAS Life Sciences Group stock | $6.97

Own SELLAS Life Sciences Group stock in just a few minutes.

Fact checked

SELLAS Life Sciences Group, Inc is a biotechnology business based in the US. SELLAS Life Sciences Group shares (SLS) are listed on the NASDAQ and all prices are listed in US Dollars. SELLAS Life Sciences Group employs 5 staff and has a market cap (total outstanding shares value) of USD$81.5 million.

How to buy shares in SELLAS Life Sciences Group

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for SELLAS Life Sciences Group. Find the stock by name or ticker symbol: SLS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until SELLAS Life Sciences Group reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.97, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of SELLAS Life Sciences Group, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of SELLAS Life Sciences Group. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

SELLAS Life Sciences Group share price

Use our graph to track the performance of SLS stocks over time.

SELLAS Life Sciences Group shares at a glance

Information last updated 2020-12-29.
Latest market closeUSD$6.97
52-week rangeUSD$1.455 - USD$8.58
50-day moving average USD$4.9212
200-day moving average USD$3.2954
Wall St. target priceUSD$10
PE ratio 0.6181
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.351

Buy SELLAS Life Sciences Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy SELLAS Life Sciences Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SELLAS Life Sciences Group price performance over time

Historical closes compared with the close of $6.97 from 2020-12-18

1 week (2021-01-13) N/A
1 month (2020-12-24) 10.46%
3 months (2020-10-20) N/A
6 months (2020-07-20) N/A
1 year (2020-01-20) N/A
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

Is SELLAS Life Sciences Group under- or over-valued?

Valuing SELLAS Life Sciences Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of SELLAS Life Sciences Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

SELLAS Life Sciences Group's P/E ratio

SELLAS Life Sciences Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, SELLAS Life Sciences Group shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

SELLAS Life Sciences Group financials

Gross profit TTM USD$0
Return on assets TTM -54.6%
Return on equity TTM -220.18%
Profit margin 0%
Book value $0.84
Market capitalisation USD$81.5 million

TTM: trailing 12 months

Shorting SELLAS Life Sciences Group shares

There are currently 1.3 million SELLAS Life Sciences Group shares held short by investors – that's known as SELLAS Life Sciences Group's "short interest". This figure is 127.4% up from 553,845 last month.

There are a few different ways that this level of interest in shorting SELLAS Life Sciences Group shares can be evaluated.

SELLAS Life Sciences Group's "short interest ratio" (SIR)

SELLAS Life Sciences Group's "short interest ratio" (SIR) is the quantity of SELLAS Life Sciences Group shares currently shorted divided by the average quantity of SELLAS Life Sciences Group shares traded daily (recently around 10.5 million). SELLAS Life Sciences Group's SIR currently stands at 0.12. In other words for every 100,000 SELLAS Life Sciences Group shares traded daily on the market, roughly 120 shares are currently held short.

However SELLAS Life Sciences Group's short interest can also be evaluated against the total number of SELLAS Life Sciences Group shares, or, against the total number of tradable SELLAS Life Sciences Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SELLAS Life Sciences Group's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 SELLAS Life Sciences Group shares in existence, roughly 110 shares are currently held short) or 0.1061% of the tradable shares (for every 100,000 tradable SELLAS Life Sciences Group shares, roughly 106 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against SELLAS Life Sciences Group.

Find out more about how you can short SELLAS Life Sciences Group stock.

SELLAS Life Sciences Group share dividends

We're not expecting SELLAS Life Sciences Group to pay a dividend over the next 12 months.

Have SELLAS Life Sciences Group's shares ever split?

SELLAS Life Sciences Group's shares were split on a 1:50 basis on 8 November 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SELLAS Life Sciences Group shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for SELLAS Life Sciences Group shares which in turn could have impacted SELLAS Life Sciences Group's share price.

SELLAS Life Sciences Group share price volatility

Over the last 12 months, SELLAS Life Sciences Group's shares have ranged in value from as little as $1.455 up to $8.58. A popular way to gauge a stock's volatility is its "beta".

SLS.US volatility(beta: 1.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SELLAS Life Sciences Group's is 1.6821. This would suggest that SELLAS Life Sciences Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

SELLAS Life Sciences Group overview

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site